TR201911293T4 - Asit sfingomiyelinaz yetmezliğinin tedavi edilmesine yönelik doz artırımlı enzim repleasman terapisi. - Google Patents

Asit sfingomiyelinaz yetmezliğinin tedavi edilmesine yönelik doz artırımlı enzim repleasman terapisi. Download PDF

Info

Publication number
TR201911293T4
TR201911293T4 TR2019/11293T TR201911293T TR201911293T4 TR 201911293 T4 TR201911293 T4 TR 201911293T4 TR 2019/11293 T TR2019/11293 T TR 2019/11293T TR 201911293 T TR201911293 T TR 201911293T TR 201911293 T4 TR201911293 T4 TR 201911293T4
Authority
TR
Turkey
Prior art keywords
dose
acid sphingomyelinase
insufficiency
treating acid
escalation enzyme
Prior art date
Application number
TR2019/11293T
Other languages
English (en)
Inventor
H Schuchman Edward
J Desnick Robert
f cox Gerald
P Andrews Laura
M Murray James
Original Assignee
Genzyme Corp
Icahn School Med Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43625265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201911293(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp, Icahn School Med Mount Sinai filed Critical Genzyme Corp
Publication of TR201911293T4 publication Critical patent/TR201911293T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Dermatology (AREA)

Abstract

Buluş asit sfingomiyelinaz yetmezliğine (ASMD) sahip insan süjelerin, ve özellikle Niemann Pick hastalığının (NPD) nörolojik olmayan belirtilerine, ve belirli yapılandırmalarda NPD tip B'ye sahip olan hastaların tedavisine yönelik asit sfingomiyelinaz (ASM) kullanılarak doz artırımlı enzim replasman terapisi ile ilgilidir.
TR2019/11293T 2009-08-28 2010-08-28 Asit sfingomiyelinaz yetmezliğinin tedavi edilmesine yönelik doz artırımlı enzim repleasman terapisi. TR201911293T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23811309P 2009-08-28 2009-08-28

Publications (1)

Publication Number Publication Date
TR201911293T4 true TR201911293T4 (tr) 2019-08-21

Family

ID=43625265

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/11293T TR201911293T4 (tr) 2009-08-28 2010-08-28 Asit sfingomiyelinaz yetmezliğinin tedavi edilmesine yönelik doz artırımlı enzim repleasman terapisi.

Country Status (26)

Country Link
US (9) US8349319B2 (tr)
EP (3) EP3482767B1 (tr)
JP (7) JP5955219B2 (tr)
KR (5) KR20200034828A (tr)
CN (3) CN106047835A (tr)
AU (5) AU2010286550B2 (tr)
BR (1) BR112012004377A2 (tr)
CA (1) CA2773133A1 (tr)
CL (1) CL2012000495A1 (tr)
CY (1) CY1122128T1 (tr)
DK (2) DK3482767T3 (tr)
ES (2) ES2738859T3 (tr)
FR (1) FR22C1062I2 (tr)
HR (2) HRP20211992T1 (tr)
HU (3) HUE046598T2 (tr)
IL (3) IL300625A (tr)
LT (2) LT3482767T (tr)
MX (1) MX356873B (tr)
NL (1) NL301211I2 (tr)
PL (2) PL3482767T3 (tr)
PT (2) PT2470199T (tr)
RU (3) RU2731616C2 (tr)
SI (2) SI3482767T1 (tr)
TR (1) TR201911293T4 (tr)
WO (1) WO2011025996A2 (tr)
ZA (2) ZA201201435B (tr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006007560A2 (en) 2004-07-01 2006-01-19 University Of Pennsylvania Targeted protein replacement for the treatment of lysosomal storage disorders
US20080228056A1 (en) 2007-03-13 2008-09-18 Michael Blomquist Basal rate testing using frequent blood glucose input
US7751907B2 (en) 2007-05-24 2010-07-06 Smiths Medical Asd, Inc. Expert system for insulin pump therapy
US8221345B2 (en) 2007-05-30 2012-07-17 Smiths Medical Asd, Inc. Insulin pump based expert system
PL3252161T3 (pl) 2007-06-06 2022-03-07 Genzyme Corporation Terapia genowa dla lizosomalnych chorób spichrzeniowych
KR20200034828A (ko) * 2009-08-28 2020-03-31 이칸 스쿨 오브 메디슨 엣 마운트 시나이 산성 스핑고미엘리나제 결핍을 치료하기 위한 투여량 단계적 증가 효소 대체 요법
US8882701B2 (en) 2009-12-04 2014-11-11 Smiths Medical Asd, Inc. Advanced step therapy delivery for an ambulatory infusion pump and system
WO2011146143A2 (en) 2010-05-21 2011-11-24 Ohmx Corporation Detection of cancer by assaying psa enzymatic activity
RU2018104472A (ru) 2011-03-18 2019-02-22 Джензим Корпорейшн Ингибиторы глюкозилцерамид-синтазы
ES2791760T3 (es) 2011-09-07 2020-11-05 Sinai School Medicine Ceramidasa y diferenciación celular
EP2780716B1 (en) 2011-11-15 2019-07-31 Centogene AG Method for the diagnosis of niemann-pick disease
LT2854910T (lt) 2012-06-01 2020-05-25 Icahn School Of Medicine At Mount Sinai Ceramido lygiai infekcijos gydymo ir prevencijos metu
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
PT2968479T (pt) * 2013-03-14 2019-08-07 Icahn School Med Mount Sinai Composições terapêuticas de ceramidase ácida e métodos de fabrico e utilização
JO3713B1 (ar) 2013-03-15 2021-01-31 Genzyme Corp أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
US10302664B2 (en) * 2013-05-14 2019-05-28 Centogene Ag Method for the diagnosis of Niemann-Pick disease
CA2914751C (en) * 2013-06-07 2023-10-03 Genzyme Corporation Marker for acid sphingomyelinase disorders and uses thereof
JP6984854B2 (ja) * 2015-10-08 2021-12-22 国立大学法人千葉大学 ニーマン・ピック病ｃ型を予防または治療するための医薬組成物
US10569016B2 (en) 2015-12-29 2020-02-25 Tandem Diabetes Care, Inc. System and method for switching between closed loop and open loop control of an ambulatory infusion pump
CN111344003B (zh) * 2017-08-24 2024-05-07 建新公司 酸性鞘磷脂酶缺乏症患者中异常骨病症的治疗
KR20200058510A (ko) 2017-10-02 2020-05-27 데날리 테라퓨틱스 인크. 효소 대체 요법 효소를 포함하는 융합 단백질
UY38238A (es) 2018-05-25 2019-12-31 Genzyme Corp Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida
KR20230043024A (ko) 2020-07-24 2023-03-30 젠자임 코포레이션 벤글루스타트를 포함하는 제약 조성물

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039388A (en) 1976-06-04 1977-08-02 The United States Of America As Represented By The Government Diagnostic test for Niemann-Pick disease
US4082781A (en) 1976-06-04 1978-04-04 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of 2-alkanoylamino-4-nitrophenyl phosphorylcholine-hydroxide
IL74761A0 (en) 1984-04-13 1985-06-30 Hughes Howard Med Inst Human phenylalanine hydroxylase cdna clones,their production and their use in diagnosing classical phenylketonuria
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4863195A (en) * 1987-10-02 1989-09-05 Capozzola Carl A Identification tag
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
US5484719A (en) 1991-08-26 1996-01-16 Edible Vaccines, Inc. Vaccines produced and administered through edible plants
US5612487A (en) 1991-08-26 1997-03-18 Edible Vaccines, Inc. Anti-viral vaccines expressed in plants
US6034298A (en) 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5716614A (en) 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
EP0865499B1 (en) 1995-09-14 2009-03-18 Virginia Tech Intellectual Properties, Inc. Production of lysosomal enzymes in plant-based expression systems
JP2820106B2 (ja) 1996-02-29 1998-11-05 日本電気株式会社 トラヒックシェーパ装置
IL155588A0 (en) 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
US20050032211A1 (en) 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
CN100410268C (zh) 1998-12-23 2008-08-13 博伊斯汤普生植物研究所 免疫原性的乙型肝炎表面抗原在转基因植物中的表达
US6537785B1 (en) * 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
AU2001250856A1 (en) 2000-03-17 2001-10-03 Charles Arntzen Expression of recombinant human acetylcholinesterase in transgenic plants
US20020095135A1 (en) * 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
AR034413A1 (es) * 2000-08-25 2004-02-25 Nestor Abel Chamoles Metodo para determinar la actividad de las enzimas lisosomales
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US7001994B2 (en) * 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
JP4641705B2 (ja) 2001-04-30 2011-03-02 ザイストール セラピューティクス， インコーポレイテッド 治療的タンパク質の亜細胞標的化
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
IES20011101A2 (en) * 2001-12-21 2003-06-25 Japkinstill Services Ltd A Bi-directional Messaging System
AU2003224880A1 (en) * 2002-04-05 2003-10-27 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy
US7585518B2 (en) 2002-11-19 2009-09-08 Kimberly-Clark Worldwide, Inc. Products and methods for maintaining or increasing ceramide levels in skin
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US7951557B2 (en) 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
JP2007518396A (ja) 2003-06-12 2007-07-12 ジェンザイム・コーポレーション 増加した活性を有する修飾されたヒト酸性スフィンゴミエリナーゼおよびその製造方法
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) * 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
WO2005051331A2 (en) * 2003-11-25 2005-06-09 Mount Sinai School Of Medicine Of New York University Chaperone-based therapy for niemann-pick disease
CA2583691A1 (en) 2004-10-13 2006-04-20 Protalix Ltd. System and method for production of antibodies in plant cell culture
US7615224B2 (en) 2004-12-02 2009-11-10 Women's And Children's Hospital Multiplex-bead complex for determination of lysosomal storage disorders
AU2006333135A1 (en) 2005-12-15 2007-07-12 The Research Foundation Of State University Of New York Enzymatic methods for measuring plasma and tissue sphingomylelin and phosphatidylcholine
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
EP1981546B1 (en) 2006-02-06 2014-06-04 The Medical Research and Infrastructure Fund of the Tel-Aviv Sourasky Medical Center Enzyme replacement therapy for treating lysosomal storage diseases
LT1988823T (lt) * 2006-02-09 2018-12-10 Genzyme Corporation Lėtas intraventrikuliarinis pateikimas
AU2007215080A1 (en) 2006-02-13 2007-08-23 Fraunhofer Usa, Inc. Influenza antigens, vaccine compositions, and related methods
JP5302189B2 (ja) 2007-04-27 2013-10-02 長瀬産業株式会社 スフィンゴミエリナーゼ
EP2323652A2 (en) 2008-08-06 2011-05-25 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
SI2889043T1 (sl) 2008-12-16 2019-08-30 Genzyme Corporation Sintetične vmesne spojine za pripravo konjugatov oligosaharid-protein
KR20200034828A (ko) * 2009-08-28 2020-03-31 이칸 스쿨 오브 메디슨 엣 마운트 시나이 산성 스핑고미엘리나제 결핍을 치료하기 위한 투여량 단계적 증가 효소 대체 요법
WO2012177778A1 (en) * 2011-06-20 2012-12-27 Mount Sinai School Of Medicine Anti-tnf- therapy for the mucopolysaccharidoses and other lysosomal disorders

Also Published As

Publication number Publication date
US20190151419A1 (en) 2019-05-23
US20220305091A1 (en) 2022-09-29
JP2018076322A (ja) 2018-05-17
EP3482767A1 (en) 2019-05-15
FR22C1062I2 (fr) 2023-12-29
CN105999238A (zh) 2016-10-12
JP2024026214A (ja) 2024-02-28
HRP20191385T1 (hr) 2019-11-01
RU2731616C2 (ru) 2020-09-07
PT2470199T (pt) 2019-08-07
US20160120957A1 (en) 2016-05-05
NL301211I1 (nl) 2022-12-28
SI3482767T1 (sl) 2022-03-31
JP2013502933A (ja) 2013-01-31
KR20120081077A (ko) 2012-07-18
ZA201201435B (en) 2020-05-27
HUS2200050I1 (hu) 2022-12-28
RU2015145255A3 (tr) 2019-08-12
US10188705B2 (en) 2019-01-29
RU2015145255A (ru) 2019-01-11
US20210077593A1 (en) 2021-03-18
KR102608546B1 (ko) 2023-12-04
JP2023012499A (ja) 2023-01-25
EP3998078A1 (en) 2022-05-18
ES2902229T3 (es) 2022-03-25
IL266915A (en) 2019-07-31
KR20200034828A (ko) 2020-03-31
US8709408B2 (en) 2014-04-29
CY1122128T1 (el) 2020-11-25
BR112012004377A2 (pt) 2017-12-12
EP2470199B1 (en) 2019-05-22
JP2020090513A (ja) 2020-06-11
HUE057440T2 (hu) 2022-05-28
US8349319B2 (en) 2013-01-08
IL266915B2 (en) 2023-07-01
MX2012002449A (es) 2012-03-14
HUE046598T2 (hu) 2020-03-30
DK3482767T3 (da) 2021-12-20
JP2016153408A (ja) 2016-08-25
FR22C1062I1 (fr) 2023-02-03
AU2010286550B2 (en) 2016-05-19
JP5955219B2 (ja) 2016-07-20
CN106047835A (zh) 2016-10-26
LT3482767T (lt) 2022-01-10
MX356873B (es) 2018-06-18
AU2020256322A1 (en) 2020-11-12
ZA201601362B (en) 2017-05-31
CA2773133A1 (en) 2011-03-03
JP7167281B2 (ja) 2022-11-08
IL218324B (en) 2019-05-30
KR102094253B1 (ko) 2020-03-31
DK2470199T3 (da) 2019-08-05
KR102608551B1 (ko) 2023-12-04
EP2470199A2 (en) 2012-07-04
WO2011025996A3 (en) 2012-03-15
AU2016216625A1 (en) 2016-09-15
SI2470199T1 (sl) 2019-11-29
US20130078230A1 (en) 2013-03-28
PL3482767T3 (pl) 2022-02-14
KR20230164773A (ko) 2023-12-04
WO2011025996A9 (en) 2011-08-25
AU2020256322B2 (en) 2024-02-29
IL266915B1 (en) 2023-03-01
KR20210107153A (ko) 2021-08-31
AU2024201085A1 (en) 2024-03-07
PL2470199T3 (pl) 2019-11-29
JP2022003065A (ja) 2022-01-11
IL300625A (en) 2023-04-01
ES2738859T3 (es) 2020-01-27
JP6251307B2 (ja) 2017-12-20
AU2018204156B2 (en) 2020-07-16
US20130078231A1 (en) 2013-03-28
JP6952810B2 (ja) 2021-10-20
RU2012111823A (ru) 2013-10-10
KR20220104271A (ko) 2022-07-26
RU2569744C2 (ru) 2015-11-27
HRP20211992T1 (hr) 2022-04-01
CL2012000495A1 (es) 2014-02-07
EP2470199A4 (en) 2013-03-27
PT3482767T (pt) 2021-12-29
US20180055916A1 (en) 2018-03-01
US20110052559A1 (en) 2011-03-03
US8658162B2 (en) 2014-02-25
US9114139B2 (en) 2015-08-25
JP7395693B2 (ja) 2023-12-11
NL301211I2 (nl) 2023-02-02
EP3482767B1 (en) 2021-10-06
AU2016216625B2 (en) 2018-07-05
US20140335070A1 (en) 2014-11-13
RU2020128994A (ru) 2022-03-02
AU2010286550A1 (en) 2012-03-15
AU2018204156A1 (en) 2018-06-28
IL218324A0 (en) 2012-04-30
US9655954B2 (en) 2017-05-23
CN102596232A (zh) 2012-07-18
LT2470199T (lt) 2019-10-10
WO2011025996A2 (en) 2011-03-03

Similar Documents

Publication Publication Date Title
TR201911293T4 (tr) Asit sfingomiyelinaz yetmezliğinin tedavi edilmesine yönelik doz artırımlı enzim repleasman terapisi.
NZ602471A (en) Antagonists of activin-actriia and uses for increasing red blood cell levels
NZ630009A (en) Angiogenesis using placental stem cells
NZ602798A (en) Treatment of sarcoidosis using placental stem cells
HRP20120887T1 (en) Adherent cells from adipose or placenta tissues and use thereof in therapy
CO6660423A2 (es) Composiciones y métodos para tratar la enfermedad de gaucher
MX348797B (es) Microorganismos probioticos como agentes activos para mejorar el brillo de la tez de la piel.
ATE554155T1 (de) Wasch-, reinigungs- und pflegemittel
WO2011046616A3 (en) Methods for modulating bacterial infection
MX346450B (es) Composiciones y métodos para el tratamiento de la enfermedad celíaca.
MX2011007397A (es) Inhibidores de dpp-iv para el tratamiento de la diabetes en pacientes pediatricos.
MX2019005130A (es) Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmaceuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabeticos tipificados geneticamente.
MX2014008156A (es) Metodos de tratamiento de sintomas conductuales de trastornos neurologicos y trastornos mentales.
BR112014007675A2 (pt) tratamento de doença articular degenerativa
MX2012001346A (es) Polipeptidos del factor ix modificados y usos de los mismos.
BR112013004700A2 (pt) método para prevenir ou tratar doenças ou distúrbios cardiovasculares
BR112013012697A2 (pt) "método para diminuir expressão, produção ou secreção de um fator angiogênico ou fator hipertrófico ou ambos por células-tronco mesenquimais, métodos para diminuir um efeito inibidor, um efeito deletério, e um efeito de apoptose de células-tronco mesenquimais, método para aumentar um efeito estimulador de células-tronco mesenquimais, composição, e, método para preparar cartilagem em um indivíduo diagnosticado com cartilagem doente ou danificada."
SV2010003694A (es) Tiazolopiridin-2-iloxi-fenil y tiazolopirazin-2-iloxi-fenil aminas como moduladores de leucotrieno a4 hidrolasa
MX2010005211A (es) Metodos y sistemas para el cuidado oral.
EA201590088A1 (ru) Стволовые клетки и клетки поджелудочной железы, используемые для лечения инсулинозависимого сахарного диабета
BR112013009660A8 (pt) Proteína de fusão com fator de atividade ix, sequência de dna e vetor recombinante
EA201591522A1 (ru) Лечение реакции трансплантат против хозяина у подвергаемых трансплантации пациентов
MX2010003071A (es) Uso de n-fenilamidas de acido 2-sulfonilaminobenzoico sustituidas con sulfonilo en el tratamiento del dolor.
MX2010000938A (es) Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del ácido 4-hidroxi-4-metil-piperidin-1-carboxílico para el tratamiento del trastorno por estrés postraumático.
EA201500501A1 (ru) Несущий корпус для лекарственного средства и способ его изготовления